^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    oxaliplatin

    i
    Other names: 1 OHP, 1670 RB, L OHP, NSC 266046, PR 54780, RP 54780, SR 96669, 1670 RB7
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, DNA cross linking agent
    Related drugs:
    3d
    ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases (clinicaltrials.gov)
    P2, N=120, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    3d
    Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=35, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    3d
    LAP-NET1: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=43, Completed, University Hospital, Grenoble | Active, not recruiting --> Completed
    Trial completion
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    5-fluorouracil • oxaliplatin • irinotecan • NP137 • levoleucovorin calcium
    3d
    Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU (clinicaltrials.gov)
    P2, N=583, Recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    4d
    SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P1, N=25, Recruiting, University of Miami | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    4d
    A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2/3, N=120, Not yet recruiting, Nanjing Sanhome Pharmaceutical, Co., Ltd.
    New P2/3 trial
    |
    Avastin (bevacizumab) • capecitabine • Stivarga (regorafenib) • oxaliplatin
    4d
    A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). (clinicaltrials.gov)
    P3, N=507, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Mar 2026 --> Sep 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative
    |
    capecitabine • oxaliplatin • Vyloy (zolbetuximab-clzb)
    4d
    An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma. (PubMed, ESMO Gastrointest Oncol)
    Patients will receive T-DXd (5.4 mg/kg, day 1) combined with nivolumab (360 mg/body, day 1) and CAPOX (capecitabine: 750 mg/m2 twice daily, days 1-14 and oxaliplatin: 70 mg/m2, day 1), every 3 weeks. Hypothesis testing assumes a null ORR of 58% and an alternative ORR of 80%. The planned sample size is 28 patients treated with RP2D.
    P1/2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin
    4d
    Continuum of care and survival in patients with metastatic colorectal cancer: results of the real-world prospective, longitudinal cohort PROMETCO study. (PubMed, ESMO Gastrointest Oncol)
    Between mCRC diagnosis and death or withdrawal, patients were frequently exposed to fluoropyrimidine (99.0%), irinotecan (96.2%), oxaliplatin (88.4%), anti-vascular endothelial growth factor (78.7%) and anti-epidermal growth factor receptor (40.1%). PROMETCO provided information on real-world prescribing patterns and efficacy. OS from mCRC diagnosis and PFS from 3L and beyond were similar to previous long-term follow-up data from clinical trials.
    Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type • RAS mutation
    |
    oxaliplatin • irinotecan
    4d
    Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy. (PubMed, ESMO Gastrointest Oncol)
    Gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX) therapies are widely used to treat advanced pancreatic ductal adenocarcinoma (PDAC)...In Japanese real-world data, GnP showed superior TTP compared with FFX for advanced PDAC. TP53 status may serve as a prognostic biomarker in patients receiving GnP therapy.
    Journal • HEOR • Real-world evidence
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMAD4 (SMAD family member 4)
    |
    TP53 mutation • TP53 wild-type
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium
    4d
    Anti-colorectal cancer effects of IRX4 and sensitivity studies to oxaliplatin. (PubMed, Front Immunol)
    These findings suggest that IRX4 may be a prognostic biomarker and therapeutic target in CRC. Moreover, IRX4 might regulate CRC progression and chemosensitivity by inhibiting the NF-κB /EGFR pathway, suggesting its potential as a therapeutic target to improve chemotherapeutic efficacy in CRC.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    oxaliplatin
    4d
    Integrated network pharmacology and experimental verification to reveal the mechanisms of curcumin in the treatment of colorectal cancer. (PubMed, Front Pharmacol)
    Furthermore, curcumin significantly inhibited tumor growth (p=0.039) and exhibited a synergistic antitumor effect with oxaliplatin in vivo. This study comprehensively elucidates the molecular mechanisms by which curcumin exerts its therapeutic effects in CRC via modulation of ferroptosis and Wnt/β-catenin signaling pathway. These findings provide novel mechanistic insights and support the translational potential of curcumin in preclinical and clinical frameworks.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4) • SERPINE1 (Serpin Family E Member 1) • SLC7A11 (Solute Carrier Family 7 Member 11) • SIRT1 (Sirtuin 1) • MMP3 (Matrix metallopeptidase 3)
    |
    oxaliplatin